Schwab IR, Friedlaender M, McCulley J, et al.
Department of Ophthalmology, University of California-Davis, 4860 Y Street, Suite 2400, Sacramento, CA 95817, USA.
SourceOphthalmology 2003 Mar; 110(3)
To compare the efficacy and safety of 0.5% levofloxacin ophthalmic solution (QUIXIN) with 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Prospective, randomized, active-controlled, double-masked, multicenter study.
Four hundred twenty-three patients with a clinical diagnosis of bacterial conjunctivitis were enrolled.
Patients were randomly assigned to receive either 0.5% levofloxacin (n = 211) or 0.3% ofloxacin (n = 212) for 5 days (every 2 hours on days 1 and 2 and every 4 hours on days 3-5). Conjunctival cultures were obtained, and ocular signs and symptoms were evaluated on day 1 (baseline), days 3 to 5 (interim), and days 6 to 10 (final). End point was defined as the last evaluable observation.
MAIN OUTCOME MEASURES
Primary microbial and clinical outcomes were based on culture results and resolution of cardinal signs, respectively. Secondary efficacy assessments included evaluations of ocular signs and symptoms.
Two hundred eight patients (levofloxacin, n = 109; ofloxacin, n = 99) were evaluated for efficacy. Microbial eradication rates were significantly greater in the 0.5% levofloxacin treatment group compared with the 0.3% ofloxacin group at both the final visit (89% vs. 80%, P = 0.034) and at end point (90% vs. 81%; P = 0.038). Treatment with 0.5% levofloxacin was significantly more effective in resolving photophobia than was 0.3% ofloxacin treatment (94% vs. 73%, P = 0.006). Both study medications were well tolerated, with a low incidence of adverse events.
Although clinical cure rates in the 0.5% levofloxacin and 0.3% ofloxacin treatment groups were similar, a 5-day treatment regimen with 0.5% levofloxacin achieved microbial eradication rates that were statistically superior to those attained with 0.3% ofloxacin. Despite the higher concentration of active drug in 0.5% levofloxacin versus 0.3% ofloxacin, there was no difference between treatment groups in the incidence of treatment-related adverse events.
MeshAdolescentAdultAgedAged, 80 and overAnti-Infective AgentsBacteriaChildChild, PreschoolConjunctivaConjunctivitis, BacterialDouble-Blind MethodFemaleHumansInfantMaleMiddle AgedOfloxacinOphthalmic SolutionsProspective StudiesSafetyTreatment Outcome
Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't